Literature DB >> 33899124

Deciphering the selective binding mechanisms of anaplastic lymphoma kinase-derived neuroblastoma tumor neoepitopes to human leukocyte antigen.

Wenchao Tian1, Xianxian Liu2, Lulu Wang3, Bufeng Zheng1, Kun Jiang1, Guoyong Fu1, Wenyu Feng4.   

Abstract

Neuroblastoma (NB), as a metastatic form of solid tumor, has a high fatality rate found in early childhood. The two anaplastic lymphoma kinase (ALK) neoepitopes nonamer and decamer used in cancer immunotherapy against NB cancer can selectively bind to the human leukocyte antigen (HLA-B*15:01) groove with high affinities, whereas the native self-peptide is unable to interact with the HLA-B*15:01. Here, we performed molecular dynamics (MD) simulations and subsequent molecular mechanics-generalized born surface area (MM-GBSA) binding free energy calculations to explore the selective binding mechanisms of nonamer and decamer to the HLA-B*15:01 against the self-peptide. MD simulations revealed the significant conformational dynamics of the self-peptide in the HLA-B*15:01 groove against the nonamer and decamer. Binding free energy calculations showed that the binding affinities of HLA-B*15:01-neoepitope complexes were followed in the order decamer > nonamer > self-peptide. Detailed analysis of HLA-B*15:01-neoepitope structural complexes showed that compared to the nonamer, the self-peptide tended to move outward to the solvent, whereas the decamer moved deep to the HLA-B*15:01 groove. These different dynamic observations of the ALK neoepitopes can explain the distinct binding affinities of self-peptide, nonamer, and decamer to the HLA-B*15:01. The results may be useful for the design of more selective ALK neoepitopes.

Entities:  

Keywords:  Anaplastic lymphoma kinase; Binding free energy calculations; Cancer immunotherapy; Human leukocyte antigen; Molecular dynamics simulations; Neuroblastoma

Year:  2021        PMID: 33899124     DOI: 10.1007/s00894-021-04754-9

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  29 in total

Review 1.  Neuroblastoma: An Updated Review on Biology and Treatment.

Authors:  Suresh Mallepalli; Manoj Kumar Gupta; Ramakrishna Vadde
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

Review 2.  A BAG's life: Every connection matters in cancer.

Authors:  Elena Mariotto; Giampietro Viola; Carlo Zanon; Sanja Aveic
Journal:  Pharmacol Ther       Date:  2020-01-27       Impact factor: 12.310

Review 3.  Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).

Authors:  Xiaotian Kong; Peichen Pan; Huiyong Sun; Hongguang Xia; Xuwen Wang; Youyong Li; Tingjun Hou
Journal:  J Med Chem       Date:  2019-08-26       Impact factor: 7.446

4.  Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.

Authors:  Xinyi Li; Jinyuan Dai; Duan Ni; Xinheng He; Hao Zhang; Jian Zhang; Qiang Fu; Yaqin Liu; Shaoyong Lu
Journal:  Int J Biol Macromol       Date:  2019-12-06       Impact factor: 6.953

5.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.

Authors:  James A Maier; Carmenza Martinez; Koushik Kasavajhala; Lauren Wickstrom; Kevin E Hauser; Carlos Simmerling
Journal:  J Chem Theory Comput       Date:  2015-07-23       Impact factor: 6.006

6.  A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.

Authors:  Jugmohit S Toor; Arjun A Rao; Andrew C McShan; Mark Yarmarkovich; Santrupti Nerli; Karissa Yamaguchi; Ada A Madejska; Son Nguyen; Sarvind Tripathi; John M Maris; Sofie R Salama; David Haussler; Nikolaos G Sgourakis
Journal:  Front Immunol       Date:  2018-01-30       Impact factor: 7.561

7.  A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses.

Authors:  Wenjie Zhai; Xiuman Zhou; Hongfei Wang; Wanqiong Li; Guanyu Chen; Xinghua Sui; Guodong Li; Yuanming Qi; Yanfeng Gao
Journal:  Acta Pharm Sin B       Date:  2020-01-13       Impact factor: 11.413

Review 8.  Targeting uptake transporters for cancer imaging and treatment.

Authors:  Yuchen Zhang; Joanne Wang
Journal:  Acta Pharm Sin B       Date:  2019-12-16       Impact factor: 11.413

Review 9.  Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.

Authors:  Yu Fu; Qing Lin; Zhirong Zhang; Ling Zhang
Journal:  Acta Pharm Sin B       Date:  2019-09-03       Impact factor: 11.413

View more
  1 in total

1.  Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.

Authors:  Shibo Zhou; Bo Yang; Yufeng Xu; Aihua Gu; Juan Peng; Jinfeng Fu
Journal:  J Mol Model       Date:  2022-08-06       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.